Do analysts rate TELO or AVIR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, TELO or AVIR?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is TELO or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% Atea Pharmaceuticals N/A -57.01% -51.49%

Do analysts recommend PALI or TELO?

Palisade Bio presently has a consensus target price of $10.20, suggesting a potential upside of 428.50%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Palisade Bio is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PALI or TELO more profitable?

Palisade Bio's return on equity of -36.79% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% Telomir Pharmaceuticals N/A -201.23% -172.71%

Do analysts rate TELO or LRMR?

Larimar Therapeutics has a consensus price target of $15.29, suggesting a potential upside of 377.68%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09

Which has higher earnings and valuation, TELO or LRMR?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A

Is TELO or LRMR more profitable?

Larimar Therapeutics' return on equity of -134.14% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% Larimar Therapeutics N/A -134.14% -96.00%

Do analysts rate TELO or ELYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, TELO or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is TELO or ELYM more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% Eliem Therapeutics N/A -47.03% -45.97%

Do analysts prefer TELO or IRD?

Opus Genetics has a consensus price target of $10.18, indicating a potential upside of 142.42%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Opus Genetics 2 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.80

Telomir Pharmaceuticals (TELO) Competitors

$1.23 -0.01 (-0.81%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$1.24 +0.01 (+0.81%)

As of 04:00 AM Eastern

Compare

TELO vs. AVIR, PALI, LRMR, ELYM, and IRD

Should you buy Telomir Pharmaceuticals stock or one of its competitors? MarketBeat compares Telomir Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telomir Pharmaceuticals include Atea Pharmaceuticals (AVIR), Palisade Bio (PALI), Larimar Therapeutics (LRMR), Eliem Therapeutics (ELYM), and Opus Genetics (IRD). These companies are all part of the "pharmaceutical products" industry.

How does Telomir Pharmaceuticals compare to Atea Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Telomir Pharmaceuticals has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Atea Pharmaceuticals' return on equity of -57.01% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

In the previous week, Atea Pharmaceuticals had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Atea Pharmaceuticals and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat Atea Pharmaceuticals' score of 1.04 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Very Positive
Atea Pharmaceuticals	Positive

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Summary

Atea Pharmaceuticals beats Telomir Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

11.8% of Palisade Bio shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Palisade Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

In the previous week, Palisade Bio had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 2 mentions for Palisade Bio and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat Palisade Bio's score of 0.63 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Palisade Bio	Positive
Telomir Pharmaceuticals	Very Positive

Palisade Bio's return on equity of -36.79% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Telomir Pharmaceuticals has lower revenue, but higher earnings than Palisade Bio. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,340.04	-$16.78M	-$1.01	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Palisade Bio presently has a consensus target price of $10.20, suggesting a potential upside of 428.50%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Palisade Bio is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Palisade Bio beats Telomir Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Larimar Therapeutics?

Telomir Pharmaceuticals (NASDAQ:TELO) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Larimar Therapeutics has a consensus price target of $15.29, suggesting a potential upside of 377.68%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

91.9% of Larimar Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Larimar Therapeutics had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 2 mentions for Larimar Therapeutics and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat Larimar Therapeutics' score of 0.54 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Very Positive
Larimar Therapeutics	Positive

Larimar Therapeutics' return on equity of -134.14% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Larimar Therapeutics	N/A	-134.14%	-96.00%

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Summary

Larimar Therapeutics beats Telomir Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Eliem Therapeutics?

Telomir Pharmaceuticals (NASDAQ:TELO) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Telomir Pharmaceuticals and 0 mentions for Eliem Therapeutics. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat Eliem Therapeutics' score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Very Positive
Eliem Therapeutics	Neutral

Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market.

Eliem Therapeutics' return on equity of -47.03% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Summary

Telomir Pharmaceuticals beats Eliem Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Opus Genetics?

Telomir Pharmaceuticals (NASDAQ:TELO) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Telomir Pharmaceuticals' return on equity of -201.23% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Opus Genetics	-892.36%	-338.88%	-191.21%

Opus Genetics has a consensus price target of $10.18, indicating a potential upside of 142.42%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.80

15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Telomir Pharmaceuticals has higher earnings, but lower revenue than Opus Genetics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Opus Genetics	$14.20M	24.08	-$49.59M	-$1.33	N/A

In the previous week, Opus Genetics had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Opus Genetics and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat Opus Genetics' score of 0.38 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Very Positive
Opus Genetics	Neutral

Telomir Pharmaceuticals has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Summary

Opus Genetics beats Telomir Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELO vs. The Competition

Export

Metric	Telomir Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$85.28M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-4.24	17.69	22.17	24.18
Price / Sales	N/A	302.27	525.94	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	7.24	3.85	9.88	6.72
Net Income	-$10.41M	$75.85M	$3.57B	$337.19M
7 Day Performance	-3.91%	-3.99%	-2.45%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-41.71%	19.65%	26.51%	33.10%

Telomir Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELO Telomir Pharmaceuticals	0.5094 of 5 stars	$1.23 -0.8%	N/A	-39.7%	$85.28M	N/A	N/A	1	Positive News
AVIR Atea Pharmaceuticals	1.0242 of 5 stars	$4.25 -0.5%	N/A	+30.7%	$340.13M	N/A	N/A	70
PALI Palisade Bio	1.6994 of 5 stars	$1.96 +5.1%	$10.20 +421.7%	+162.2%	$339.35M	$250K	N/A	10
LRMR Larimar Therapeutics	2.4402 of 5 stars	$3.22 -2.6%	$15.29 +375.4%	+32.8%	$333.97M	N/A	N/A	30
ELYM Eliem Therapeutics	N/A	$11.20 -5.1%	N/A	+849.2%	$333.22M	N/A	N/A	9	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELO) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. AVIR, PALI, LRMR, ELYM, and IRD

How does Telomir Pharmaceuticals compare to Atea Pharmaceuticals?

Summary

How does Telomir Pharmaceuticals compare to Palisade Bio?

Summary

How does Telomir Pharmaceuticals compare to Larimar Therapeutics?

Summary

How does Telomir Pharmaceuticals compare to Eliem Therapeutics?

Summary

How does Telomir Pharmaceuticals compare to Opus Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. AVIR, PALI, LRMR, ELYM, and IRD

How does Telomir Pharmaceuticals compare to Atea Pharmaceuticals?

Which has more risk and volatility, TELO or AVIR?

Do analysts rate TELO or AVIR?

Is TELO or AVIR more profitable?

Does the media prefer TELO or AVIR?

Do insiders and institutionals hold more shares of TELO or AVIR?

Which has higher valuation and earnings, TELO or AVIR?

Summary

How does Telomir Pharmaceuticals compare to Palisade Bio?

Do insiders & institutionals hold more shares of PALI or TELO?

Which has more volatility & risk, PALI or TELO?

Does the media prefer PALI or TELO?

Is PALI or TELO more profitable?

Which has stronger valuation and earnings, PALI or TELO?

Do analysts recommend PALI or TELO?

Summary

How does Telomir Pharmaceuticals compare to Larimar Therapeutics?

Which has more risk & volatility, TELO or LRMR?

Do analysts rate TELO or LRMR?

Do institutionals and insiders believe in TELO or LRMR?

Does the media favor TELO or LRMR?

Is TELO or LRMR more profitable?

Which has higher earnings and valuation, TELO or LRMR?

Summary

How does Telomir Pharmaceuticals compare to Eliem Therapeutics?

Do institutionals and insiders have more ownership in TELO or ELYM?

Which has better valuation and earnings, TELO or ELYM?

Do analysts rate TELO or ELYM?

Does the media refer more to TELO or ELYM?

Which has more risk & volatility, TELO or ELYM?

Is TELO or ELYM more profitable?

Summary

How does Telomir Pharmaceuticals compare to Opus Genetics?

Is TELO or IRD more profitable?

Do analysts prefer TELO or IRD?

Do insiders and institutionals have more ownership in TELO or IRD?

Which has stronger earnings & valuation, TELO or IRD?

Does the media refer more to TELO or IRD?

Which has more risk and volatility, TELO or IRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools